#United States #Atlanta #Nordic Pharma #SECO 2025 #Lacrifill Gel

Overview

Nordic Pharma, Inc., a subsidiary of the Nordic Group B.V., is set to present a fascinating poster at SECO 2025, an influential optometry conference taking place from February 26 to March 2 in Atlanta, Georgia. This presentation will focus on Lacrifill® Canalicular Gel, an innovative solution designed to address treatment gaps in patients suffering from dry eye syndrome.

The Innovation Behind Lacrifill®

Lacrifill Canalicular Gel is a groundbreaking product that utilizes a proprietary formulation of hyaluronic acid (HA). This gel is uniquely packaged in a pre-filled syring, which can be easily injected through the punctum into the canaliculus, thereby providing direct relief for the tear ducts. The effectiveness of this gel is underscored by a case series presented by Dr. Mile Brujic, OD, FAAO, from Premier Vision Group, who will share insights from his work with patients experiencing refractory dry eye.

Clinical Insights

Dr. Brujic’s presentation will involve three patients who previously used dissolvable occlusive plugs for six months before transitioning to the Lacrifill Canalicular Gel. The outcomes have been promising, demonstrating significant improvements in both the signs and symptoms associated with their dry eye, post-occlusion with the gel. He stated, "Lacrifill Canalicular Gel has proven to be an exceptional tool in my practice. This case series exemplifies the positive changes I have witnessed in numerous patients regarding corneal health and comfort after treatment. Additionally, I have increased the number of occlusions I perform utilizing Lacrifill Canalicular Gel."

SECO Conference Highlights

The SECO International conference is regarded as one of the world’s largest optometric continuing education events, providing attendees with unmatched opportunities for learning, groundbreaking exhibitions, and innovative networking. Phil Gioia, President of the U.S. Team at Nordic Pharma, expressed enthusiasm about the positive results achieved through the use of Lacrifill Canalicular Gel. "We are thrilled to see optometrists utilizing Lacrifill for dry eye treatment with such excellent results,” he remarked. “Since its launch last year, we have been collaborating with optometrists, supporting the critical role they play in the management of dry eye."

Presentation Details

For those interested in exploring the advancements in dry eye treatment, the poster session will occur on February 28 from 9:45 AM to 11:45 AM at the Georgia World Congress Center, Hall A-1 and A-2, Optometry's Marketplace. After the conference, the poster will be available online at SECO University.

About Nordic Group B.V.

Nordic Group B.V. is a mid-sized, international pharmaceutical company focused on developing and marketing specialty products. The company aims to expand its portfolio through strategic development and acquisitions, establishing a foothold in areas such as ophthalmology, rheumatology, and women's health. Recently, Nordic Group has expanded its global presence through increased acquisitions outside Europe.

The Role of Nordic Pharma, Inc.

Nordic Pharma, Inc. partners with established global biopharmaceutical companies, utilizing its expertise in market launches of biotechnologically manufactured drugs, sterile production, and cutting-edge technologies. The company is part of SEVER Life Sciences, a holding company established in 2019, which unites three different yet complementary firms offering a broad range of products, pharmaceutical development services, and administration technologies.

Conclusion

In conclusion, the poster presentation at SECO 2025 marks a significant moment for both Nordic Pharma and the field of optometry. By highlighting the clinical successes of Lacrifill® Canalicular Gel, they are pioneering advancements that have the potential to enhance patient care for those challenged by dry eye conditions. For further details on product ordering or general inquiries, visit lacrifill.com or reach out to the Nordic Pharma team.